Creo Medical Group PLC Institute of Physics Award
05 July 2019 - 4:00PM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
05 July 2019
Creo Medical Group plc
("Creo" or the "Company")
Institute of Physics Award &
Royal Academy of Engineering Visiting Professor appointment
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
Chris Hancock, founder of Creo and Chief Technology Officer, has
been awarded the Katharine Burr Blodgett Medal and Prize for 2019
by the Institute of Physics ("IOP") and has been appointed as a
Visiting Professor by the Royal Academy of Engineering.
Katharine Burr Blodgett Medal and Prize
The Katharine Burr Blodgett Medal, introduced by the IOP in
2008, is awarded for outstanding and sustained contributions to the
organisation or application of physics in an industrial or
commercial context.
The 2019 Medal and Prize was awarded to Professor Hancock "for
designing and patenting an electro-surgery platform enabling
microwave and bi-polar radio frequency to be delivered to a range
of miniature endoscopic devices to treat lesions in the
gastrointestinal (GI) tract."
For the full citation:
http://www.iop.org/about/awards/gold/burr-blodgett/medallists/page_72859.html
Visiting Professor appointment
In addition, The Royal Academy of Engineering has appointed
Chris Hancock as a Visiting Professor to University College London
to deliver face-to-face teaching and mentoring for three years.
Engineering undergraduates will benefit from an enhanced
understanding of the role of engineering and the way it is
practised, along with its challenges and demands and the programme
also enables engineers to contribute to postgraduate teaching and
curriculum development, to continue the impact of the scheme beyond
the length of the appointment.
About Chris Hancock
Chris has over 20 years of experience in medical device
development including four years at Gyrus Group plc in his role as
Senior Engineer. Chris holds a personal Chair in the Medical
Microwave Systems Research Group at Bangor University. Chris is a
Fellow of the Institute of Physics, a Chartered Physicist, Fellow
of the Institute of Engineering and Technology, a Chartered
Engineer and a Senior Member of the IEEE. He is a named inventor
and lead author on over 500 patents/patent applications and journal
publications and was recently named in the Sunday Times Maserati
100, its annual list of inspiring entrepreneurs.
Chris Hancock, Chief Technology Officer and Founder of Creo
Medical, said: "It is a great honour to receive the Katharine Burr
Blodgett Medal and Prize from the Institute of Physics, and I am
delighted to have been appointed as a Royal Academy of Engineering
Visiting Professor to UCL. I am incredibly grateful for the support
that the team at Creo have provided as we have developed a platform
to apply microwave and RF energy to surgical endoscopy and bring
this to fruition in a commercial suite of products. Most important
of all is that these combined efforts have created the first of
those products which is already improving patient outcomes around
the world."
Creo was also included within Wales Business Insider's list of
the 'Most Exciting Companies in Wales', which highlights 50
innovative, fast-moving Welsh businesses. The Most Exciting
Companies list was published in the July 2019 edition of the
magazine.
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Lianne Cawthorne Mob: +44 (0)7515 909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAVZLFBKDFBBBF
(END) Dow Jones Newswires
July 05, 2019 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2023 to Jul 2024